These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

388 related articles for article (PubMed ID: 29929486)

  • 41. Plasma levels of matrix metalloproteinase-9 in chronic urticaria patients correlate with disease severity and C-reactive protein but not with circulating histamine-releasing factors.
    Tedeschi A; Asero R; Lorini M; Marzano AV; Cugno M
    Clin Exp Allergy; 2010 Jun; 40(6):875-81. PubMed ID: 20214668
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Increased circulating levels of matrix metalloproteinase (MMP)-8, MMP-9, and pro-inflammatory markers in patients with metabolic syndrome.
    Gonçalves FM; Jacob-Ferreira AL; Gomes VA; Casella-Filho A; Chagas AC; Marcaccini AM; Gerlach RF; Tanus-Santos JE
    Clin Chim Acta; 2009 May; 403(1-2):173-7. PubMed ID: 19254704
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Simultaneous up-regulation of matrix metalloproteinases 1, 2, 3, 7, 8, 9 and tissue inhibitors of metalloproteinases 1, 4 in serum of patients with chronic obstructive pulmonary disease.
    Navratilova Z; Zatloukal J; Kriegova E; Kolek V; Petrek M
    Respirology; 2012 Aug; 17(6):1006-12. PubMed ID: 22591289
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Matrix metalloproteinase-9 expression correlates with prognosis and involved in ovarian cancer cell invasion.
    Hu X; Li D; Zhang W; Zhou J; Tang B; Li L
    Arch Gynecol Obstet; 2012 Dec; 286(6):1537-43. PubMed ID: 22832979
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Tissue MMP-2 and MMP-9 [corrected] are better prognostic factors than serum MMP-2/TIMP-2--complex or TIMP-1 [corrected] in stage [corrected] I-III lung carcinoma.
    Hoikkala S; Pääkkö P; Soini Y; Mäkitaro R; Kinnula V; Turpeenniemi-Hujanen T
    Cancer Lett; 2006 May; 236(1):125-32. PubMed ID: 15982804
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Matrix metalloproteinases, their tissue inhibitors and colorectal cancer staging.
    Baker EA; Bergin FG; Leaper DJ
    Br J Surg; 2000 Sep; 87(9):1215-21. PubMed ID: 10971431
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Plasma levels of the MMP-9:TIMP-1 complex as prognostic biomarker in breast cancer: a retrospective study.
    Thorsen SB; Christensen SL; Würtz SO; Lundberg M; Nielsen BS; Vinther L; Knowles M; Gee N; Fredriksson S; Møller S; Brünner N; Schrohl AS; Stenvang J
    BMC Cancer; 2013 Dec; 13():598. PubMed ID: 24330623
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Gelatinases and their tissue inhibitors in ovarian tumors; TIMP-1 is a predictive as well as a prognostic factor.
    Rauvala M; Puistola U; Turpeenniemi-Hujanen T
    Gynecol Oncol; 2005 Dec; 99(3):656-63. PubMed ID: 16112717
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Matrix-metalloproteinases and their inhibitors are elevated in severe sepsis: prognostic value of TIMP-1 in severe sepsis.
    Hoffmann U; Bertsch T; Dvortsak E; Liebetrau C; Lang S; Liebe V; Huhle G; Borggrefe M; Brueckmann M
    Scand J Infect Dis; 2006; 38(10):867-72. PubMed ID: 17008230
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Serum levels and tissue expression of matrix metalloproteinase 2 (MMP-2) and tissue inhibitor of metalloproteinases 2 (TIMP-2) in colorectal cancer patients.
    Groblewska M; Mroczko B; Gryko M; Pryczynicz A; Guzińska-Ustymowicz K; Kędra B; Kemona A; Szmitkowski M
    Tumour Biol; 2014 Apr; 35(4):3793-802. PubMed ID: 24395652
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Serum matrix metalloproteinases MMP-2 and MMP-9 and metalloproteinase tissue inhibitors TIMP-1 and TIMP-2 in diabetic nephropathy.
    Rysz J; Banach M; Stolarek RA; Pasnik J; Cialkowska-Rysz A; Koktysz R; Piechota M; Baj Z
    J Nephrol; 2007; 20(4):444-52. PubMed ID: 17879211
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The role of matrix metalloproteinase MMP-9 and TIMP-2 tissue inhibitor of metalloproteinases as serum markers of bladder cancer.
    Ramón de Fata F; Ferruelo A; Andrés G; Gimbernat H; Sánchez-Chapado M; Angulo JC
    Actas Urol Esp; 2013 Sep; 37(8):480-8. PubMed ID: 23916137
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Serum TIMP-1, TIMP-2, and MMP-1 in patients with systemic sclerosis, primary Raynaud's phenomenon, and in normal controls.
    Young-Min SA; Beeton C; Laughton R; Plumpton T; Bartram S; Murphy G; Black C; Cawston TE
    Ann Rheum Dis; 2001 Sep; 60(9):846-51. PubMed ID: 11502611
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Peripheral blood levels of matrix and inflammatory mediators are elevated in Tunisian patients with acute coronary syndromes.
    Zayani Y; Allal-Elasmi M; Jacob MP; Zidi W; Zaroui A; Feki M; Mourali S; Mechmech R; Kaabachi N
    Clin Lab; 2013; 59(1-2):169-75. PubMed ID: 23505923
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Pre-treatment serum and plasma levels of matrix metalloproteinase 9 (MMP-9) and tissue inhibitor of matrix metalloproteinases 1 (TIMP-1) in gastric cancer patients.
    Mroczko B; Groblewska M; Łukaszewicz-Zajac M; Bandurski R; Kedra B; Szmitkowski M
    Clin Chem Lab Med; 2009; 47(9):1133-9. PubMed ID: 19728856
    [TBL] [Abstract][Full Text] [Related]  

  • 56. A novel prognostic index in colorectal cancer defined by serum carcinoembryonic antigen and plasma tissue inhibitor of metalloproteinases-1.
    Nielsen HJ; Christensen IJ; Brünner N
    Scand J Gastroenterol; 2010; 45(2):200-7. PubMed ID: 20095885
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Profiles of matrix metalloproteinases and their inhibitors in plasma of patients with dementia.
    Lorenzl S; Buerger K; Hampel H; Beal MF
    Int Psychogeriatr; 2008 Feb; 20(1):67-76. PubMed ID: 17697439
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Serum levels of matrix metalloproteinase-9 and its tissue inhibitor (TIMP-1) in acute disseminated encephalomyelitis.
    Ichiyama T; Kajimoto M; Suenaga N; Maeba S; Matsubara T; Furukawa S
    J Neuroimmunol; 2006 Mar; 172(1-2):182-6. PubMed ID: 16321449
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Significance of circulating matrix metalloproteinase-9 to tissue inhibitor of metalloproteinases-2 ratio as a predictor of disease progression in patients with metastatic renal cell carcinoma receiving sunitinib.
    Miyake H; Nishikawa M; Tei H; Furukawa J; Harada K; Fujisawa M
    Urol Oncol; 2014 Jul; 32(5):584-8. PubMed ID: 24680659
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Serum matrix metalloproteinase-3 and tissue inhibitor of metalloproteinases-1 as potential markers of carotid atherosclerosis in infraclinical hyperlipidemia.
    Beaudeux JL; Giral P; Bruckert E; Bernard M; Foglietti MJ; Chapman MJ
    Atherosclerosis; 2003 Jul; 169(1):139-46. PubMed ID: 12860260
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.